Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 10, Issue 3 (Vol.10 No.3 Oct 2021)
rbmb.net 2021, 10(3): 488-494 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Temur A A, Rashid F A. Irisin and Carcinoembryonic Antigen (CEA) as Potential Diagnostic Biomarkers in Gastric and Colorectal Cancers. rbmb.net 2021; 10 (3) :488-494
URL: http://rbmb.net/article-1-732-en.html
URL: http://rbmb.net/article-1-732-en.html
Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq.
Abstract: (3012 Views)
Background: Carcinoembryonic antigen (CEA) is a common gastrointestinal tumor biomarker. Irisin is adipo-myokines that has been suggested to have a potential role in cancer development. However, limited studies test irisin as biomarker in gastric and colorectal cancers. Therefore, this study aims to investigate whether CEA and irisin could be a potential diagnostic biomarker in gastric and colorectal cancer.
Methods: A case-control study consists of 90 subjects, 21 gastric cancer patients, 49 colorectal cancer patients and 20 control. Serum CEA was detected by fluorescence immunoassay (FIA) kit. Serum irisin was determined by enzyme-linked immunosorbent assay (ELISA) kit.
Results: Serum CEA increases significantly and serum irisin decreases significantly in gastric and colorectal cancer patients. According to Receiver Operating Characteristic (ROC) curve analysis, in gastric cancer, the area under curve of CEA is 1.00 (95% CI, 1.000-1.000, p< 0.0001). The diagnostic
cut-off of CEA is< 3.08 ng/ml with %100 sensitivity and 100% specificity. The area under curve of irisin is 0.94 (95% CI, 0.8177-1.000, p< 0.0001). The cut-off of irisin is> 30.2 ng/ml with %90 sensitivity and 100%, specificity. In colorectal cancer, the area under curve of CEA is 0.99 (95% CI, 0.9866-1.000, p<0.0001) and the diagnostic value< 2.6 ng/ml with %98 sensitivity and %100 specificity. The area under curve of irisin is 0.96 (95% CI, 0.9155-1.000, p< 0.0001). The diagnostic cut-off of irisin is> 41.9 ng/ml with 88.1sensitivity and 90.5 specificity.
Conclusions: CEA and irisin could be powerful potential diagnostic biomarkers which would be use for early detection of gastric and colorectal cancers.
Methods: A case-control study consists of 90 subjects, 21 gastric cancer patients, 49 colorectal cancer patients and 20 control. Serum CEA was detected by fluorescence immunoassay (FIA) kit. Serum irisin was determined by enzyme-linked immunosorbent assay (ELISA) kit.
Results: Serum CEA increases significantly and serum irisin decreases significantly in gastric and colorectal cancer patients. According to Receiver Operating Characteristic (ROC) curve analysis, in gastric cancer, the area under curve of CEA is 1.00 (95% CI, 1.000-1.000, p< 0.0001). The diagnostic
cut-off of CEA is< 3.08 ng/ml with %100 sensitivity and 100% specificity. The area under curve of irisin is 0.94 (95% CI, 0.8177-1.000, p< 0.0001). The cut-off of irisin is> 30.2 ng/ml with %90 sensitivity and 100%, specificity. In colorectal cancer, the area under curve of CEA is 0.99 (95% CI, 0.9866-1.000, p<0.0001) and the diagnostic value< 2.6 ng/ml with %98 sensitivity and %100 specificity. The area under curve of irisin is 0.96 (95% CI, 0.9155-1.000, p< 0.0001). The diagnostic cut-off of irisin is> 41.9 ng/ml with 88.1sensitivity and 90.5 specificity.
Conclusions: CEA and irisin could be powerful potential diagnostic biomarkers which would be use for early detection of gastric and colorectal cancers.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2021/06/10 | Accepted: 2021/08/23 | Published: 2021/12/5
Received: 2021/06/10 | Accepted: 2021/08/23 | Published: 2021/12/5
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [DOI:10.3322/caac.21660] [PMID]
2. ShaoY, Sun X, He Y, Liu C, Liu H. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PloS one. 2015;10(7): e0133830. [DOI:10.1371/journal.pone.0133830] [PMID] [PMCID]
3. Rashid FA, Mahdi S, Mahdy SM, Salim AT. Effect of Obesity on Plasma Alkaline Phosphatase Activity in Breast Cancer. Reports of Biochemistry and Molecular Biology. 2021;10(2):307-313. [DOI:10.52547/rbmb.10.2.307] [PMID] [PMCID]
4. Park YA, Kang YL, Nam KK, Seung HB, Seung KS, Chang WC. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13(5):645-50. [DOI:10.1245/ASO.2006.03.090] [PMID]
5. Huh JW, Oh BR, Kim HR, Kim UJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol. 2010;101(5):396-400. [DOI:10.1002/jso.21495] [PMID]
6. Shen M, Wang H, Wei K, Zhang J, You C. Five common tumor biomarkers and CEA for diagnosing early gastric cancer: A protocol for a network meta-analysis of diagnostic test accuracy. Medicine (Baltimore). 2018;97(19):e0577. [DOI:10.1097/MD.0000000000010577] [PMID] [PMCID]
7. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8. [DOI:10.1038/nature10777] [PMID] [PMCID]
8. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Crujeiras AB, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013;8(4):e60563. [DOI:10.1371/journal.pone.0060563] [PMID] [PMCID]
9. Wen MS, Wang C, Lin S, Hung K. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013;8(5):e64025. [DOI:10.1371/journal.pone.0064025] [PMID] [PMCID]
10. Rashid FA, Abbas HJ, Naser NA, Ali HA. Effect of Long-Term Moderate Physical Exercise on Irisin between Normal Weight and Obese Men. Scientific World Journal. 2020;2020:1897027. [DOI:10.1155/2020/1897027] [PMID] [PMCID]
11. Shelbaya S, Shady MMA, Nasr MS, Behket MM, Abd Al-Mageed Y, Abbas M. Study of Irisin Hormone Level in Type 2 Diabetic Patients and Patients with Diabetic Nephropathy. Curr Diabetes Rev. 2018;14(5):481-486. [DOI:10.2174/1573399813666170829163442] [PMID]
12. Osella AR, Colaianni G, Correale M, Pesole PL, Bruno I, Buongiorno C, et al. Irisin Serum Levels in Metabolic Syndrome Patients Treated with Three Different Diets: A Post-Hoc Analysis from a Randomized Controlled Clinical Trial. Nutrients. 2018;10(7):844. [DOI:10.3390/nu10070844] [PMID] [PMCID]
13. Park HK, Zaichenko L, Brinkoetter M, Sahin-Efe A, Joung KE, Tsoukas MA, et al. Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome. J Clin Endocrinol Metab. 2013; 98(12):4899-4907. [DOI:10.1210/jc.2013-2373] [PMID] [PMCID]
14. Yan B, Shi X, Zhang H, Pan L, Ma Z, Liu S, et al. Association of Serum Irisin with Metabolic Syndrome in Obese Chinese Adults. PLOS ONE. 2014;9(4):e94235. [DOI:10.1371/journal.pone.0094235] [PMID] [PMCID]
15. Rashid FA, Alhashemi WKH, Al- Saffar AT, Salman EA, Najeeb DA. Obesity and Breast Cancer Risk in Different Menopausal Status: A Review. Biochemical and cellular Archives. 20(1):1875-1878
16. Roomi AB, Nori W, Hamed RM. Lower Serum Irisin Levels Are Associated with Increased Osteoporosis and Oxidative Stress in Postmenopausal. Rep Biochem Mol Biol. 2021;10(1):13-19. [DOI:10.52547/rbmb.10.1.13] [PMID] [PMCID]
17. Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G. Review of Research on the Role of Irisin in Tumors. Onco Targets Ther. 2020;13:4423-4430. [DOI:10.2147/OTT.S245178] [PMID] [PMCID]
18. Aydin S, Kuloglu T, Ozercan MR, Albayrak S, Aydin S, Bakal U. Irisin immunohistochemistry in gastrointestinal system cancers. Biotech Histochem. 2016;91(4):242-50. [DOI:10.3109/10520295.2015.1136988] [PMID]
19. Shao L, Lin H, Chen J, Song H, Zhang Y, We F, et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2017;485(3):598-605. [DOI:10.1016/j.bbrc.2016.12.084] [PMID]
20. Liu J, Song N, Huang Y, Chen Y. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep. 2018;8(1):15247. [DOI:10.1038/s41598-018-33229-w] [PMID] [PMCID]
21. Aslan R, Alp HH, Eryilmaz R, Huyut Z, Sevim M, Araz Ş, et al. Can the Irisin be a Biomarker for Prostate Cancer?. A Case Control Study. Asian Pac J Cancer Prev. 2020;21(2):505-509. [DOI:10.31557/APJCP.2020.21.2.505] [PMID] [PMCID]
22. Provatopoulou X, Georgiou GP, Kalogera E, Kalles V, Matiatou MA, Papapanagiotou I, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1):898. [DOI:10.1186/s12885-015-1898-1] [PMID] [PMCID]
23. Altay DU, Keha EE, Karagüzel E, Menteşe A, Yaman SO, Alver A. The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. Int Braz J Urol. 2018;44(4):734-739. [DOI:10.1590/s1677-5538.ibju.2017.0404] [PMID] [PMCID]
24. Dolscheid-Pommerich RC, Manekller S, Walgenbach-Brünagel GK, Kalff CJ, Hartmann G, Wagner BS, et al. Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays. Anticancer Research. 2017;37(1):353-359. [DOI:10.21873/anticanres.11329] [PMID]
25. Shahidi S, Hejazi J, Moghimi M, Borji S, Zabihian S, Fathi M, et al. Circulating Irisin Levels and Redox Status Markers in Patients with Gastric Cancer: A Case-Control Study. Asian Pac J Cancer Prev. 2020;21(10):2847-2851. [DOI:10.31557/APJCP.2020.21.10.2847] [PMID] [PMCID]
26. Zhu H, Liu M, Zhang N, Pan H, Lin G, Li N, et al. Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients with or without Obesity. Front Physiol. 2018;9:1125-1125. [DOI:10.3389/fphys.2018.01125] [PMID] [PMCID]
27. Gannon NP, Vanghan RA, Garcia-Smith R, Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behaviour in vitro. Int J Cancer. 2015;136(4):E197-202. [DOI:10.1002/ijc.29142] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
